论文部分内容阅读
HUMAN PLASMA is a source material that is crucial for the production of unique therapeutic fractionated products.Indeed,plasma contains hundreds of proteins ensuring many physiological functions.The most abundant proteins,albumin and immunoglobulin G (IgG),are present at about 35 and 10 g/L,respectively,representing about 80% of all plasma proteins.However,other important therapeutic proteins include the coagulation factors (factor Ⅷ (FⅧ); FⅨ; Von Willebrand Factor (VWF),fibrinogen) various protease inhibitors (alpha 1-antitrypsin; antithrombin; C1-esterase) and anticoagulants (protein C) which exhibit potent physiological activity.Currently over 10 different protein therapeutics can be extracted from plasma to treat life-threatening diseases or injuries associated to bleeding and thrombotic disorders,immunological diseases,infectious conditions as well as tissue degenerating diseases,thus addressing the clinical needs of many patients.Considering that plasma is a very valuable resources available in limited supply at national levels,it is important,for ethical,medical,and economical reasons,to optimize its use by producing,at satisfactory yields,an appropriate range of safe products meeting the needs of patients.
HUMAN PLASMA is a source material that is crucial for the production of unique therapeutic fractionated products. Indeed, plasma contains hundreds of proteins ensuring many physiological functions. The most abundant proteins, albumin and immunoglobulin G (IgG), are present at about 35 and 10 (FⅧ); F IX; Von Willebrand Factor (VWF), fibrinogen) various protease inhibitors (alpha 1- antitrypsin; antithrombin; and anticoagulants (protein C) which exhibit potent physiological activity. Current over 10 different protein therapeutics can be extracted from plasma to treat life-threatening diseases or injuries associated to bleeding and thrombotic disorders, immunological diseases, infectious conditions as well as tissue degenerating diseases, thus addressing the clinical needs of many patients .Considering that plasma is a very valuable resources available in limited supply at national levels, it is important, for ethical, medical, and economical reasons, to optimize its use by producing, at satisfactory yields, an appropriate range of safe products meeting the needs of patients.